SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending following a report that the company is preparing a potential takeover bid for eBay, fueling intense debate among investors regarding the feasibility of such a large-scale acquisition. Community members are actively split between those anticipating a major catalyst for a short squeeze and skeptics questioning the financial mechanics and strategic logic behind combining the two legacy retailers.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is currently trending due to a surge in community discussion surrounding its potential for quantum-resistant utility and recent institutional attention, fueling speculation about a possible breakout. While some investors are actively accumulating the coin at lower levels, others remain skeptical, leading to a polarizing debate between those expecting a significant price squeeze and those predicting further downside.

eBay, Inc. is a commerce company, whose platforms include an online marketplace and its localized counterparts, including off-platform businesses in South Korea, Japan, and Turkey, as well as eBay’s suite of mobile apps. It offers a platform for various product categories, including parts and accessories, collectibles, fashion, electronics, and home & garden. eBay generates revenue mainly through fees from sales, payment processing, and advertising. The company was founded by Pierre Morad Omidyar in September 1995 and is headquartered in San Jose, CA.

EBay Inc.

eBay Inc

eBay is trending following media reports that GameStop is potentially preparing an acquisition bid for the e-commerce giant, sparking intense debate among the community regarding the feasibility of such a large-scale deal. Retail investors and market commentators are actively questioning how GameStop would finance the acquisition while debating the strategic logic of combining these legacy brands.

Veil Cash is a privacy application leveraging zk-SNARKs on Base L2, enabling verified depositors to achieve privacy and anonymity within a pool of trusted users.  Veil Cash is a non-custodial privacy protocol on Base L2. Veil Cash's goal will be enabling verified users to achieve privacy and anonymity from trusted pools.  Veil is a set of smart contracts that will allow users that are deemed as verified users to deposit into the protocol. Users can later withdraw their deposits from another address without creating a link between these two addresses.   Verified users are those who meet certain criteria based on both on-chain and off-chain data.

Veil-project

VEIL is trending as community members rally behind its focus on privacy technology and decentralized network security. Investors are actively discussing the project's potential within the Base ecosystem and the growing interest in privacy-focused assets.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit Therapeutics is experiencing high trading activity as investors react to the company's recent BLA submission for its lead drug candidate, ivonescimab, and its new clinical trial collaboration with GSK. The community is focused on the potential for this drug to disrupt the lung cancer treatment market, with active discussions centering on the upcoming interim progression-free survival data and the significance of the BLA filing ahead of a major industry conference.

International Business Machines Corp. is an information technology company, which engages in the provision of integrated solutions that leverage information technology and knowledge of business processes. It operates through the following segments: Software, Consulting, Infrastructure, Financing, and Other. The Software segment combines hybrid cloud platform and software solutions to help clients become more data-driven, and to automate, secure, and modernize their environments. The Consulting segment focuses on integrating skills on strategy, experience, technology and operations by domain and industry. The Infrastructure segment offers solutions for hybrid cloud and is the foundation of the hybrid cloud stack. Infrastructure is optimized for infusing AI into mission-critical transactions and tightly integrated with IBM Software including Red Hat for accelerated hybrid cloud benefits. The Financing segment refers to the client and commercial financing, facilitating IBM clients’ acquisition of IT systems, software, and services. The company was founded by Charles Ranlett Flint and Thomas J. Watson Sr. on June 16, 1911 and is headquartered in Armonk, NY.

International Business Machines Corp.

IBM is trending as investors digest a series of positive analyst initiations and technical partnerships, while the community focuses on its long-term potential in AI consulting and quantum computing. Despite recent price volatility, many market participants view the stock as undervalued and are tracking its momentum ahead of upcoming earnings.

Rayls is a Layer-1 blockchain ecosystem designed for financial institutions to bridge traditional finance (TradFi) and decentralized finance (DeFi). Developed by Parfin, Rayls combines a public chain, private networks, and institutional privacy nodes into a unified infrastructure that supports compliant, scalable, and privacy-preserving asset tokenization and settlement. Its architecture connects regulated banks and payment systems with public DeFi liquidity while maintaining confidentiality through the Rayls Enygma privacy protocol. The network enables tokenization of real-world assets, CBDCs, and stablecoins using EVM-compatible technology, fixed USD-pegged gas fees, deterministic finality, and harmful MEV protection.

Rayls

Rayls (RLS) is seeing increased community interest and volatility surrounding its recent mainnet launch and the activation of new tokenomics, including a transaction fee burn mechanism. While some investors are optimistic about potential institutional partnerships and long-term utility, others are debating whether current price movements indicate a genuine breakout or a speculative cycle.

WorldFinancial

WorldFinancial is currently under intense community scrutiny as traders debate the impact of proposed governance votes, including potential massive token burns and long-term vesting lockups. Sentiment remains deeply divided between those viewing the project as a speculative play on political connections and critics labeling it a highly manipulated asset plagued by controversy and governance concerns.

Solana is a high-performance Layer 1 blockchain designed for mass adoption by providing a fast, secure, and low-cost environment for decentralized applications. It distinguishes itself by scaling globally without the use of complex sharding or multiple layers, instead maintaining a single, unified ledger to avoid liquidity fragmentation. This architecture allows it to process thousands of transactions per second with sub-second finality, often at a cost of less than a penny per transaction.  The network operates on a unique hybrid model that combines Proof of Stake with an innovation called Proof of History, which functions as a decentralized clock to timestamp transactions. This system reduces the need for constant node communication, allowing the Sealevel engine to run non-conflicting smart contracts in parallel across multiple CPU cores. Further efficiency is gained through the Gulf Stream protocol, which reduces confirmation times by forwarding transactions to validators before the current block is finished.  Founded in 2017 by Anatoly Yakovenko, Solana is now supported by the Switzerland-based Solana Foundation and significant institutional investors like Andreessen Horowitz and Polychain Capital. The platform’s native token, SOL, serves as the primary currency for paying transaction fees, participating in network governance, and securing the system through staking.   Solana has also seen significant institutional adoption ranging from spot Solana ETFs to major partnerships including Visa's 2025 launch of USDC settlement on the network and the tokenization of public equity by firms like Galaxy Digital.

Solana

Solana is currently a central focus for traders as they monitor a mix of institutional sentiment and high-energy community activity around memecoins like UPDOG and other project launches. Investors are actively discussing the potential for a breakout, with many tracking how current market conditions, including staking yields and broader crypto adoption trends, will influence its next major move.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is currently driven by heightened investor interest in its lead drug candidate, soquelitinib, as community discussions focus on its potential as a first-in-class oral treatment for atopic dermatitis and other inflammatory indications. Investors are closely monitoring upcoming clinical data readouts and institutional analyst activity, while the stock experiences significant volatility fueled by high short interest and speculative chatter regarding potential M&A activity.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Biotech stocks remain a hot sector for retail traders on Stocktwits,&nbsp;which collectively boast over 3.45 million followers.&nbsp;In January, several biotech names saw explosive gains as investors bet on breakthrough treatments, key partnerships, and regulatory milestones.According to Stocktwits data, these five biotech stocks saw the highest surge in retail following this month.CARGO Therapeutics Inc. (CRGX) – 445% Jump In FollowersCARGO Therapeutics, a clinical-stage biotech company focused on cancer treatments, saw its stock collapse even as retail interest surged.&nbsp;In January, the FDA cleared its Investigational New Drug (IND) application for CRG-023, a novel tri-specific CAR T therapy designed to tackle relapse factors in B-cell malignancies.&nbsp;However, the company later announced it would discontinue a Phase II trial of its lead candidate, firi-cel, after an ad hoc safety analysis revealed an unfavorable benefit-risk profile.&nbsp;Wall Street analysts issued downgrades, and CARGO’s stock is on track to plunge more than 76% in January — its worst month since going public in November 2023.&nbsp;Short interest stands at 15.1%, according to Koyfin data.Sana Biotechnology Inc. (SANA) – 185% Jump In FollowersSana Biotechnology, which focuses on engineered cell therapies, captured investor attention with a potential&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sana-biotech-stock-triples-after-type-1-diabetes-trial-data/chGBWsVRZO">breakthrough</a> in type 1 diabetes.&nbsp;The company demonstrated earlier this month that its hypoimmune edits allowed islet cell transplant survival without immunosuppression.&nbsp;Analysts praised the findings, driving the stock up roughly 114% in January — its best month since its March 2021 market debut.&nbsp;Short interest is at 16.6%.Silexion Therapeutics Corp. (SLXN) – 92% Jump In FollowersSilexion, an oncology-focused biotech developing RNA interference therapies, gained momentum after releasing preclinical data on a second-generation siRNA candidate, SIL-204.&nbsp;The treatment&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/slxn-stock-hits-record-low-after-pricing-5m-offering/chGtwKoRng">showed</a> synergistic efficacy when combined with first-line chemotherapy for pancreatic cancer.&nbsp;Although the stock gained just 2% in January, it marked its best month since November.&nbsp;Short interest remains low at 2.4%.AEON Biopharma Inc. (AEON) – 81% Jump In FollowersAEON Biopharma is developing ABP-450, a botulinum toxin complex similar to Evolus’ Jeuveau, for medical indications such as chronic migraine.&nbsp;Retail traders appeared to buy the dip after AEON priced a $20 million public offering earlier this month, which initially sent shares tumbling.&nbsp;The stock is headed for a 77% drop in January, its worst month since going public via a SPAC merger in July 2023.&nbsp;Short interest is just 0.2%, according to Koyfin.Kairos Pharma (KAPA) – 78% Jump In FollowersKairos Pharma, a clinical-stage biopharmaceutical company, saw retail interest soar this month after breaking key resistance levels and securing crucial investments.&nbsp;The company is testing its lead candidate, ENV105 — which targets a protein linked to resistance in cancer treatments — in Phase 2 trials for castrate-resistant prostate cancer and Phase 1 trials for lung cancer.The stock gained momentum following CEO John Yu’s positive comments at an investor healthcare summit this month and the completion of a $3.5 million PIPE transaction.&nbsp;Kairos shares are set to decline 2.6% in January, marking their worst month since October.&nbsp;Short interest remains&nbsp;negligible at 0.1%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Hand holding test tube over stock data on computer monitor. | Image source: Getty Images

Retail Traders Flocked To These 5 Biotech Stocks In January — Here’s Why

Biotech remains a high-risk, high-reward sector, and this month’s top draws reflect retail’s appetite for stocks with major clinical and regulatory catalysts.

Equity

Biotech remains a high-risk, high-reward sector, and this month’s top draws reflect retail’s appetite for stocks with major clinical and regulatory catalysts.


The biotech sector remains a hotbed for retail investor interest, with over 3.4 million users following these stocks on Stocktwits. Last week, the below three companies saw the highest increases in retail following:Kairos Pharma Ltd. (+83%)Kairos Pharma, a clinical-stage biopharmaceutical company focused on cancer therapeutics, saw the most spike in retail chatter.&nbsp;The company is testing its lead candidate, ENV105 — which targets a protein linked to resistance in cancer treatments — in Phase 2 trials for castrate-resistant prostate cancer and Phase 1 trials for lung cancer.Retail interest soared last week after Kairos broke key resistance levels and secured crucial investments.&nbsp;The stock surged nearly 120% last Monday following positive comments from CEO John Yu at an investor healthcare summit.&nbsp;Additionally, the company completed a $3.5 million PIPE transaction, which the CEO said would ensure the continued progress of its clinical trials and asset development.&nbsp;Despite these gains, Kairos has lost 21% of its value since its NYSE debut in September.OS Therapies Inc. (+39%)Shares of OS Therapies jumped after the company reported positive clinical trial data for its OST-HER2 candidate, which targets a rare bone cancer that spreads to the lungs.&nbsp;Following the announcement, Maxim analyst Jason McCarthy raised the firm’s price target to $15 from $8, maintaining a ‘Buy’ rating.&nbsp;The data has positioned OS Therapies to meet with the FDA by the end of the first quarter of 2025 to discuss the possibility of filing for accelerated approval.The company is focused on oncology treatments, with OST-HER2 being its lead immunotherapy asset. It leverages listeria bacteria’s immune-stimulatory effects to target the HER2 protein in cancer cells.AEON Biopharma Inc. (+19%)AEON Biopharma is a company developing the proprietary botulinum toxin complex ABP-450, a biosimilar to Evolus’ Jeuveau, approved for cosmetic use, but AEON is developing it for medical indications.&nbsp;The company’s manufacturing partner, Daewoong, produces ABP-450 in FDA-approved facilities under current Good Manufacturing Practices (cGMP).Although there were no specific catalysts driving the recent spike, it appears that retail investors were buying the dip after the company priced a public offering to raise $20 million earlier this month, which had caused the stock to slide.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Kairos, OS Therapies, AEON See Highest Weekly Spike In Retail Following Among Biotechs: Here's Why

Cancer treatments, FDA breakthroughs, and other developments fueled a sharp spike in interest for these biotech players, as investors bet on promising clinical data and strategic moves.

Cryptocurrencies were on fire last week and therefore it should come as no surprise that Stocktwits users turned their attention increasingly toward the crypto and allied space. Among the 10 stocks that saw the biggest increase in watcher count on Stocktwits, four were cryptocurrencies and two were Bitcoin miners.Here’s a compilation of stocks/cryptos that were closely followed by retail last week along with their watcher count:<ul><li>Dogecoin (<a class="mention" data-mention="$DOGE.X" data-symbol-id="DOGE.X" href="https://stocktwits.com/symbol/DOGE.X" target="_blank">$DOGE.X</a>) (336,178)</li><li>SPDR S&amp;P 500 ETF Trust (<a class="mention" data-mention="$SPY" data-symbol-id="SPY" href="https://stocktwits.com/symbol/SPY" target="_blank">$SPY</a>) (537,941)</li><li>Bitcoin (<a class="mention" data-mention="$BTC.X" data-symbol-id="BTC.X" href="https://stocktwits.com/symbol/BTC.X" target="_blank">$BTC.X</a>) ($601,174)</li><li>Ripple (<a class="mention" data-mention="$XRP.X" data-symbol-id="XRP.X" href="https://stocktwits.com/symbol/XRP.X" target="_blank">$XRP.X</a>) (174,221)</li><li>Innovation Beverage Group Ltd. (<a class="mention" data-mention="$IBG" data-symbol-id="IBG" href="https://stocktwits.com/symbol/IBG" target="_blank">$IBG</a>) (1,260)</li><li>Tesla, Inc. (<a class="mention" data-mention="$TSLA" data-symbol-id="TSLA" href="https://stocktwits.com/symbol/TSLA" target="_blank">$TSLA</a>) (980,127)</li><li>PepeCoin (<a class="mention" data-mention="$PEPE.X" data-symbol-id="PEPE.X" href="https://stocktwits.com/symbol/PEPE.X" target="_blank">$PEPE.X</a>) (17,692)</li><li>Kairos Pharma Ltd. (<a class="mention" data-mention="$KAPA" data-symbol-id="KAPA" href="https://stocktwits.com/symbol/KAPA" target="_blank">$KAPA</a>) (1,076)</li><li>Mara Holdings Ltd. (<a class="mention" data-mention="$MARA" data-symbol-id="MARA" href="https://stocktwits.com/symbol/MARA" target="_blank">$MARA</a>) (147,043)</li><li>BTC Digital Ltd. (<a class="mention" data-mention="$BTCT" data-symbol-id="BTCT" href="https://stocktwits.com/symbol/BTCT" target="_blank">$BTCT</a>) (4,228)</li></ul>Dogecoin:&nbsp;Dogecoin, a meme coin, was on a tear last week as it went past the $0.40 level before pulling back since the mid-week. The retail crowd are factoring in the meme crypto breaking above its May 2021 highs of $0.74.&nbsp;SPY: The SPY, which is an exchange-traded fund that tracks the broader S&amp;P 500 Index, closed at a record high of $598.76 last Monday. The ETF has come under pressure since then amid fears that the Federal Reserve may give rate cuts a pass at the December meeting. As the year draws to the close and the market enters a seasonally strong period, retail interest in the ETF has been on the rise.Bitcoin:&nbsp;Donald Trump’s victory in the Nov. 5 election has set in motion broad-based buying in the crypto space amid hopes his policies would be more crypto-friendly. Bitcoin rose to a record high past the $93K level last week before pulling back to the $90K level. It has started the new week on a firmer note and has rebounded toward the $92K level.Ripple: Blockchain company Ripple’s native coin, the XRP, rallied past the $1 against the U.S. dollar last week amid hopes that SEC Chair Gary Gensler would be replaced. The current SEC Chair has gone after Ripple and the regulator has an ongoing lawsuit against the company for raising&nbsp;more than $1.3 billion in 2013 by selling XRP in an unregistered public offering.&nbsp;Innovation Beverage: Australian beverage maker Innovation Beverage, which sells domestically and in the U.S., saw its Nasdaq-listed shares jump 40% last week. The gains have been accompanied by a surge in volumes traded. Following a recent initial public offering, the stock was listed on Sept. 26.Retailers on the Stocktwits see scope for further upside as some of them pointed to the stock being a subject of interest on WallStreetBets reddit forum.Tesla: Trump’s victory led to a surge in Tesla shares past the $350 mark (on an intraday basis) last week but they have pulled back since then. Tesla investors view Elon Musk’s closeness to Trump as a positive for the stock even as the company’s electric-vehicle business is awaiting an inflection.PepeCoin:&nbsp;PepeCoin, another meme coin that has generated interest among retailers, more than doubled in the seven sessions that ended Nov. 9, coinciding with the presidential election. It topped $5 on Nov. 9 but has retreated since then and traded around the $4 mark.&nbsp;&nbsp;Kairos Pharma: Shares of California-based nano-cap oncology-focused clinical-stage biotech Kairos surged past $2 on Tuesday on above-average volume, with retail frenzy propping up the stock.. The buying continued in the next session before moderating. Kairos is a newly public company and was listed in mid-September.&nbsp;Mara Holdings:&nbsp;Bitcoin miner Mara’s shares plunged on Wednesday after the company reported a third-quarter revenue miss. Retail, however, is betting on the company in the hopes that the Bitcoin rally could help the miner stage a comeback.BTC Digital:&nbsp; BTC Digital shares soared over 950% to $19.27 in the week ended Nov. 15, rising from under $2 in the previous week. Retailers on the Stocktwits are bullish on the bitcoin miner.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/10-stocks-with-biggest-message-volume-on-stocktwits/cJ4HwPIRQP">10 Most Active Stocks On Stockwits Last Week With Message Volume Spurt</a>For updates and corrections email newsroom@stocktwits.com&nbsp;

Trump trades have continued to evince retail attention. 

10 Stocks/Cryptos With Biggest Increases In Followers On Stocktwits Last Week

Dogecoin, SPY, Bitcoin, Ripple and Innovation Beverage were among the securities that drew retail attention last week.

Kairos Pharma Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of novel and transformative drug therapies to treat cancer. It focuses on the research and development of immunotherapies for oncology. The company was founded by John S. Yu on June 17, 2013 and is headquartered in Los Angeles, CA.

KAPA
Kairos Pharma Ltd.

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest KAPA News

KAPAKairos Pharma Ltd.